Hi tp. I don't hold this but it has a peripheral interest to me because I hold PSD. Biotechs generally are in a bad way. That's probably the main reason. Apart from the obvious MBP & CMQ, look at PSD, EPT, ACU, GTG, to name only the ones on my watchlist. There might also be an element of pessimism about SRX's prospects as well. Although PSD is concentrating on primary liver cancer and SRX on secondary at present, to be quite frank about it, PSD's treatment looks superior in many ways, and I'm not aware of any medical reasons that preclude PSD's technology being used on secondary tumours in future. Still, I'd say that a plunging biotech sector is by far the main reason SRX is suffering.
Pezz
SRX Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
